TruAlt Bioenergy Limited promoter group entity Nirani Holdings Private Limited (NHPL) has increased its shareholding in the company to 2.25% following an open market acquisition on September 28, 2026.

The latest transaction involved the purchase of 1,22,032 equity shares at an average price of ₹458.05 per share. The total value of this specific transaction aggregated to ₹5,57,36,895.68, executed through the National Stock Exchange (NSE).

Stakeholding details

Prior to this transaction, NHPL held 18,09,612 equity shares, representing a 2.11% stake in the company. The recent purchase has raised the total holding to 19,31,644 equity shares, equivalent to 2.25% of the company's paid-up capital.

Regulatory disclosure

The transaction was disclosed under Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The intimation was made by Vijaykumar Nirani, Director of Nirani Holdings Private Limited, and acknowledged by Monu Kumar, Company Secretary and Compliance Officer of TruAlt Bioenergy Limited.

The mode of acquisition was recorded as "On Market (Through Stock Exchange)" with the trade executed on the NSE. No derivatives trading was reported by the promoter group entity during this period.

TruAlt Bioenergy Limited has paid ₹5.49 lakh in fines to BSE and NSE to resolve non-compliance issues related to board composition and meeting intimations. The company restored regulatory compliance by appointing Dr. Sarvamangala R Patil as a Non-Executive Independent Woman Director during its board meeting on September 22, 2026.

The penalties stemmed from violations of Regulation 17(1) and Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board acknowledged that the delay in appointing a woman director was not intentional but resulted from the time required to identify a suitable candidate with the requisite qualifications and independence.

Regulatory Fines and Compliance Restoration

The exchange notices highlighted two specific instances of non-compliance:

The Board noted that the lapse under Regulation 29 was procedural and inadvertent. Upon finalizing the candidate selection, Dr. Patil was appointed, thereby satisfying the requirement under Regulation 17(1). The Company Secretary confirmed that the applicable fines were paid within the stipulated timeline to avoid further penal actions such as freezing of promoter shareholding or trading suspension.

Subsidiary Investments and Strategic Context

In the same board meeting, the company approved additional investments totaling ₹29.69 crore in two subsidiaries to support growth plans. This capital infusion targets Leafiniti Bioenergy Private Limited and TruAlt Sumi Gas Private Limited.

The board authorized an investment of ₹21.42 crore in Leafiniti Bioenergy Private Limited through the subscription of 2,14,20,000 equity shares at a par value of ₹10 each. TruAlt Bioenergy currently holds a 51% stake in this joint venture with GAIL India Limited, which produces compressed biogas and allied products.

Additionally, an investment of ₹8.27 crore was approved in TruAlt Sumi Gas Private Limited (formerly TruAlt Gas Private Limited). This involves acquiring 24,31,830 equity shares at ₹34 per share, including a premium of ₹24 per share. This entity is a joint venture with Sumitomo Corporation, Japan, and has not yet commenced operations.

Subsidiary Performance Metrics

Leafiniti Bioenergy Private Limited, incorporated in February 2020, has shown significant revenue growth over the last three financial years:

TruAlt Sumi Gas Private Limited, incorporated in September 2024, remains pre-operational, with no turnover details available yet.

Governance Updates

Dr. Sarvamangala R Patil brings over two decades of experience in biotechnology, academic leadership, and government advisory roles. Her appointment is subject to shareholder approval via a special resolution for a term from September 22, 2026, to September 21, 2027. Mr. Deepak Sadhu, a Practising Company Secretary, was appointed as the Scrutinizer for the postal ballot process, with NSDL serving as the e-voting agency.

What the Numbers Show

The combined data reveals a dual focus on regulatory hygiene and operational expansion. While the company faced governance penalties totaling ₹5.49 lakh, it simultaneously committed ₹29.69 crore to subsidiary investments. The revenue jump in Leafiniti Bioenergy from ₹2,760.74 lakh in FY25 to ₹4,043.09 lakh in FY26 underscores the strategic importance of this subsidiary, justifying the majority of the new capital infusion at par value. In contrast, the premium-priced entry into TruAlt Sumi Gas reflects early-stage valuation dynamics for a non-operational venture.